The Effects of Nano-Curcumin Supplementation on Th1/Th17 Balance in Migraine Patients: A Randomized Controlled Clinical Trial Publisher Pubmed



Djalali M¹ ; Abdolahi M² ; Hosseini R³ ; Miraghajani M^{4, 5} ; Mohammadi H⁶ ; Djalali M¹
Source: Complementary Therapies in Clinical Practice Published:2020

Abstract

Background: The present study was aimed to evaluate the nano-curcumin supplementation on Th1/Th17 balance by assessment of gene expression and serum level of interferon gamma (IFN-γ) and interleukin-17 (IL-17) in migraine patients. Methods: Forty participants with episodic migraine were randomly allocated to receive 80 mg nano-curcumin (n = 20) or placebo (n = 20) in a randomized double-blind clinical trial for two months. The expression of IFN-γ and IL-17 from peripheral blood mononuclear cells and IFN-γ and IL-17 serum levels were measured, using a real-time PCR and ELISA methods, respectively. Results: Compared to placebo group, two month nano-curcumin supplementation led to a significant reduction in serum levels and expression of IL-17 mRNA (P = 0.006 & 0.04, respectively), while there was no statistical difference regarding serum levels and expression of IFN-γ mRNA. Conclusion: Nano-curcumin supplementation in migraine patients led to a significant reduction in gene expression and plasma levels of IL-17 compared to control group. © 2020